Novel prodrugs of decitabine with greater metabolic stability and less toxicity

BACKGROUND: DNA demethylation therapy is now used in practice for hematological tumors and is being developed for solid tumors. Nevertheless, it is difficult to achieve stable pharmacokinetics with the current DNA-demethylating agents, azacitidine (AZA) and decitabine (DAC), because of their rapid d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattori, Naoko, Sako, Magoichi, Kimura, Kana, Iida, Naoko, Takeshima, Hideyuki, Nakata, Yoshitaka, Kono, Yutaka, Ushijima, Toshikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670186/
https://www.ncbi.nlm.nih.gov/pubmed/31370878
http://dx.doi.org/10.1186/s13148-019-0709-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670186/
https://www.ncbi.nlm.nih.gov/pubmed/31370878
http://dx.doi.org/10.1186/s13148-019-0709-y

Ejemplares similares